Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?

Company Overview - Aclaris Therapeutics (ACRS) is a member of the Medical sector, which includes 1063 individual stocks and holds a Zacks Sector Rank of 4 [1] - Aclaris Therapeutics belongs to the Medical - Drugs industry, which consists of 191 companies and currently ranks 96 in the Zacks Industry Rank [3] Performance Metrics - Aclaris Therapeutics has returned approximately 9.5% year-to-date, outperforming the Medical sector's average return of 7.3% [2] - The Zacks Consensus Estimate for Aclaris' full-year earnings has increased by 13.9% over the past quarter, indicating improving analyst sentiment [2] - In comparison, ASLAN Pharmaceuticals Ltd. (ASLN) has seen a year-to-date increase of 36% and has a Zacks Rank of 2 (Buy) [2][3] Industry Comparison - The Medical - Drugs industry has seen an average loss of 1.3% this year, highlighting Aclaris Therapeutics' superior performance within its industry [3] - The Medical - Biomedical and Genetics industry, which includes ASLAN Pharmaceuticals, has a current rank of 84 and has moved +0.1% since the beginning of the year [3]